Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
Efficacy and Safety of Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
60 participants
Jan 23, 2024
INTERVENTIONAL
Conditions
Summary
To evaluate the efficacy and safety of tenofovir disoproxil fumarate in the treatment of Parkinson's disease. The changes of motor symptoms and the occurrence of adverse reactions in early Parkinson's disease patients who took tenofovir disoproxil fumarate and did not take Tenofovir disoproxil fumarate at different time points were compared.
Eligibility
Inclusion Criteria1
- : Parkinson's disease: Hoehn Yahr= 1 to 2.5 2: MMSE score≥24
Exclusion Criteria8
- : essential tremor, stroke, epilepsy and other well-defined neurological disorders
- : Or have received deep brain stimulation and other brain surgery
- : Abnormal liver and kidney function
- : Infected with chronic hepatitis B or AIDS (HIV-1 infection)
- : Severe depression, schizophrenia, other psychiatric disorders or drug dependence
- : Other serious physical diseases such as heart, lung, liver, kidney disease, blood disease and malignant tumor
- : Pregnant or lactating women and seniors over 65 years of age
- : Allergy or other contraindications to the investigational drug
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
take tenofovir disoproxil fumarate 300mg/d
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06356662